We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
S&P Futures
5,178.50 +11.00 (+0.21%) Dow Futures
38,308.00 +70.00 (+0.18%) Nasdaq Futures
18,221.25 +42.00 (+0.23%) Russell 2000 Futures
2,030.10 +10.30 (+0.51%) Crude Oil
85.45 -0.21 (-0.25%) Gold
2,371.90 -2.20 (-0.09%)
Amylyx Pharmaceuticals, Inc. (AMLX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.2900 |
| Open | 2.2800 |
| Bid | 2.0800 x 400 |
| Ask | 2.1200 x 800 |
| Day's Range | 2.0700 - 2.2900 |
| 52 Week Range | 2.0700 - 31.7700 |
| Volume | |
| Avg. Volume | 3,130,361 |
| Market Cap | 142.342M |
| Beta (5Y Monthly) | -0.93 |
| PE Ratio (TTM) | 3.00 |
| EPS (TTM) | 0.7000 |
| Earnings Date | May 10, 2024 - May 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.25 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AMLX
Related Research
- Amylyx Pharmaceuticals, Inc.Daily – Vickers Top Buyers & Sellers for 04/03/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moatlast yearArgus Research
ZacksThe Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals are part of the Zacks top Analyst Blog.
BenzingaAmylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited Disorder
Wednesday, Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) released interim data from the ongoing Phase 2 HELIOS trial of AMX0035 for Wolfram syndrome. Wolfram syndrome is an inherited condition that typically includes childhood-onset insulin-dependent diabetes mellitus and progressive optic atrophy. The interim data from eight participants who have completed 24 weeks of treatment demonstrated that AMX0035 had a clinically meaningful effect on key outcomes measuring the progression of diabetes, visual
ZacksBiotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News
Moderna (MRNA) and Bristol Myers (BMY) are in focus on pipeline and regulatory updates.
Business WireAmylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
CAMBRIDGE, Mass., April 10, 2024--Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial
Business WireAmylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024
CAMBRIDGE, Mass., April 08, 2024--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced the Company will host a virtual webcast with management and Fumihiko Urano, MD, PhD, Principal Investigator of the HELIOS clinical trial and the Samuel E. Schechter Professor of Medicine in the Division of Endocrinology, Metabolism & Lipid Research at Washington University School of Medicine in St. Louis to discuss interim data from HELIOS, a Phase 2 trial of AMX0035 for the
Simply Wall St.Analysts Just Slashed Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) EPS Numbers
Today is shaping up negative for Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shareholders, with the analysts...
ZacksAmylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70%
Amylyx (AMLX) makes a formal decision to remove its amyotrophic lateral sclerosis drug from the U.S. and Canadian markets. The company is expected to reduce its workforce by 70%. Its shares are trading up on the news.
Associated Press FinanceALS drug will be pulled from US market after study showed patients didn't benefit
The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn't help patients with the deadly neurological condition. Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription. “While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS," company co-founders said in a statement.
- Reuters
UPDATE 1-Amylyx Pharma to remove ALS drug from US, Canada markets
Amylyx Pharmaceuticals will withdraw its amyotrophic lateral sclerosis (ALS) drug - its only product in the market - from the U.S. and Canada after the treatment failed in a key late-stage trial. WHY IT'S IMPORTANT: The ALS drug, branded Relyvrio, was approved in 2022 after lobbying by patient groups who pointed to limited options to treat the potentially fatal disease. ALS causes progressive paralysis and death, and affects roughly 60,000 people in the U.S. and Europe.
Barrons.comAmylyx Is Cutting 70% of Its Workforce and Pulling ALS Drug From the Market
Amylyx Pharmaceuticals announced Thursday it was slashing jobs and removing its ALS drug from the market. The biotechnology company said in a securities filing that it would be cutting about 70% of its jobs, adding that it expects to incur around $19 million in severance charges following the layoffs. The drug was being developed to help slow the progression of ALS, also known as Lou Gehrig’s disease, a neurological disorder that weakens muscles.
People Also Watch
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| VTYX Ventyx Biosciences, Inc. | |||
| AKRO Akero Therapeutics, Inc. | |||
| DAWN Day One Biopharmaceuticals, Inc. | |||
| VERV Verve Therapeutics, Inc. | |||
| ACLX Arcellx, Inc. |
Similar to AMLX
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| VINC Vincerx Pharma, Inc. | |||
| EFTR eFFECTOR Therapeutics, Inc. | |||
| INZY Inozyme Pharma, Inc. | |||
| CYTK Cytokinetics, Incorporated | |||
| APLS Apellis Pharmaceuticals, Inc. |
Analyst Price Targets (6)
Upgrades & Downgrades
| Maintains | Baird: Neutral to Neutral | 4/11/2024 | |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/11/2024 | |
| Maintains | HC Wainwright & Co.: Buy to Buy | 4/8/2024 | |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/12/2024 | |
| Maintains | Deutsche Bank: Buy to Buy | 3/11/2024 | |
| Downgrade | Goldman Sachs: Buy to Neutral | 3/11/2024 |
Company Profile
43 Thorndike Street
Cambridge, MA 02141
United States
617 682 0917
https://amylyx.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 384
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
